75 results about "Antithrombins" patented technology

Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation/N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerizazion.

Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation/N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerization.

The invention discloses a reagent for detecting antithrombin activity, including reagent 1 and reagent 2, wherein: reagent 1 is a chromogenic substrate of FXa, and reagent 2 is a diluent containing FXa and heparin; wherein the chromogenic substrate of FXa is selected from From the following: CH ₃ SO ₂ ‑D‑Leu‑Gly‑Arg‑p‑nitroanilide·AcOH; CH ₃ OCO‑D‑CHG‑Gly‑Arg‑p‑nitroanilide·AcOH; CH ₃ OCO‑D‑CHA‑Gly‑Arg‑p‑nitroanilide AcOH; Benzoyl‑Ile‑Glu‑Gly‑Arg‑p‑nitroanilide HCl; Suc‑Ile‑Glu(γ‑Piperidyl)‑Gly‑Arg‑p‑nitroanilide HCl; N-α-Z-D-Arg-Gly-Arg-p-nitroanilide 2HCl; Boc-D-Arg-Gly-Arg-p-nitroanilide 2HCl; Acetyl-D-Arg-Gly-Arg-p ‑nitroanilide·2HCl; 4‑Nz‑D‑Arg‑Gly‑Arg‑p‑nitroanilide·2HCl; 4‑Mbs‑D‑Arg‑Gly‑Arg‑p‑nitroanilide·2HCl. The invention has good detection stability and repeatability, high sensitivity and accuracy, can accurately reflect the activity of antithrombin, and can find patients with abnormal antithrombin activity in the body, thereby providing a basis for treatment.

The invention belongs to the field of biological medicine in-vitro diagnosis, and particularly relates to a rapid antithrombin III detecting kit based on interaction between thrombin and a chromogenic substrate and a detecting method thereof. The kit comprises R1 reagents, an R2 reagent, a stop buffer and a chromogenic measuring card. The R2 reagent comprises a chromogenic substrate reagent. The chromogenic measuring card is provided with a colorimetric reference belt and a reaction cell. The colorimetric reference belt is provided with six color zones which have colors from deep to light and are respectively corresponding to 20%, 40%, 60%, 80%, 100% and higher than 100% of activity of the antithrombin III. Naked-eye distinctiveness of a chromogenic reaction is improved by improving a formula of the chromogenic substrate and the activity of the antithrombin III and colors distinguishable with naked eyes are correlated to obtain the colorimetric reference belt distinguishable by human eyes, and therefore the activity of the antithrombin III can be rapidly and semiquantitatively detected only by naked-eye determination without the need of using matched instruments.

The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one antithrombin activator, preferably unfractionated heparin, as well as at least one thrombin inhibitor, preferably bivalirudin.

The invention relates to a process for preparing high activity thrombin inhibitors, which comprises subjecting hirudin, the natural specific inhibitor of thrombin to DNA family restructuring, carrying out restructuring to hirudin HV1, HV2, HV3 genes, constructing reorganization library for hirudin bacteriophage display, using thrombin as coating antigen, subjecting bacteriophage reorganization library to three rounds of enriched elutriation including adsorption, elution and expansion, obtaining a plurality of bacteriophage monoclons with high affinity with thrombin through ELISA screening, carrying out pronucleus induced expression to these clones, finally detecting the antithrombogenic activity of the purification expression product.

The invention relates to a novel medicament for treating the cardio-cerebrovascular diseases and a preparation method and belongs to the technical field of preparation of the novel medicament for treating the cardio-cerebrovascular diseases. According to the invention, blood-sucking leeches, panax pseudoginseng and earthworm are used as raw materials. According to the invention, by a special preparation process of carrying out liquid nitrogen flash freezing, low-temperature superfine grinding and freeze drying before sterilization on the raw materials, the grinding fineness can reach 1 to 10 micrometers, the active ingredients of the blood-sucking leeches can be stored to the greatest extent, the active ingredients can be sufficiently adsorbed by a patient, and the novel medicament has comprehensive effects of promoting circulation, removing stasis, resisting to coagulation, reducing the pressure, lowering lipid, resisting to platelet aggregation and dissolving thrombi and is safe and reliable to take. The invention solves the problems that an existing medicament which uses leeches as the raw materials and is used for treating the cardio-cerebrovascular diseases adopts non blood-sucking leeches as the medicine and adopts a conventional grinding method, so that the antithrombase effect is poor and the curative effect is influenced; and enteric capsules only adopt the single medicine of blood-sucking leech and have poor effects of reducing the pressure, lowering the lipid and dissolving the thrombi and the preparation process ensures the active ingredients of the leeches not to be completely stored and is unbeneficial for a patient to adsorb the active ingredients.

The invention discloses a light-emitting diode (LED) phototherapy oxygenation type haemodialysis machine, which is applied to haemodialysis ultra-filtration for treating diseases of acute renal failure, chronic renal failure, uremia, hypertension, arteriosclerosis, blood hyperviscosity, histanoxia and the like and belongs to the field of medical instruments. The LED phototherapy oxygenation type haemodialysis machine mainly comprises an LED phototherapy oxygenation part device, a blood extracorporeal circulation pipeline, a dialysate supply water pipeline and a circuit controlled by a microcomputer. The machine is characterized in that: the LED phototherapy oxygenation part device is embedded into an arterial cup clamper and a dialyser clamper of the blood extracorporeal circulation pipeline by a plurality of small-sized LED multi-wavelength penetration nails. In the process of haemodialysis, part of or all of lamps in the LED phototherapy oxygenation device can operate according to a specific situation for carrying out on-line irritation on blood in the circulation pipeline by utilizing a principle of strong penetrating power of LED multi-wavelength, so that blood circulation can be improved, agglutination of erythrocytes, platelet aggregation and blood viscosity are reduced, the flow rate of blood is improved, antithrombin is activated, the content of thrombin is reduced, coagulation and hemostasis mechanisms are adjusted, and the aim of treatment is achieved.

Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation/N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerization.

The invention discloses a protective agent of human antithrombin preparation in freezing and drying process. According to the protective agent, a protective agent solution is prepared from one of solute sucrose, amino acid or salt of the amino acid by using deionized water, wherein the amino acid is lysine or hydrochloride in the salt of the lysine, or tyrosine or one of the salts in the tyrosine, or aspartic acid or one of the salts in the aspartic acid; one of the solutes is prepared into a solution by using deionized water so as to obtain the protective agent; the protective agent is added before the human antithrombin preparation is frozen and dried, the inactivation of the main antithrombin ingredient in the preparation in the freezing and drying process is effectively prevented, the activity of the antithrombin is protected, and the antithrombin has better forming appearance and redissolving clarity of the preparation after being frozen and dried.

The invention relates to an electrochemiluminescence kit for detecting a novel thrombus marker TAT (thrombin-antithrombin complex) in blood and a preparation method of the electrochemiluminescence kit. The prepared kit comprises a streptavidin coupled magnetic particle working solution, a biotin labeled thrombin antibody working solution, a terpyridyl ruthenium labeled antithrombin antibody working solution, a TAT calibrator and/or quality control substance working solution, a tripropylamine-containing electrochemiluminescence substrate solution and a cleaning solution. A luminescence system of the kit is electrochemiluminescence, a streptavidin-biotin signal amplification system is utilized, the detection sensitivity is high, the linear range is wide, the detection result repeatability ishigh, and accurate quantification of the thrombin-antithrombin compound can be achieved.

Provided is a reagent for assaying a thrombin-antithrombin complex (TAT) in a blood sample from a subject by latex agglutination assay. The reagent includes a polycation. As a result, TAT complexes can be precisely assayed while circumventing the effect of heparin. The polycation is, for example, hexadimethrine bromide, chitosans, modified dextran, aminodextran, hydroxymethyl cellulose trimethylamine, lysozyme, spermine, spermidine, polylysine, polyarginine, polyornithine, protamine sulfate, hydroxyethyl cellulose trimethylamine, heparin-binding protein, polyallylamine, polyallylamine hydrochloride, poly(diallyl dialkyl amine), polyamideamine, polyamine, polyvinylbenzyltrimethylammonium chloride, polydiallyldimethylammonium chloride, polyethyleneimine, polypropyleneimine, polypropylethyleneimine, polyimidazoline, polyvinylamine, polyvinyl pyridine, poly(acrylamide/methacryloxypropyltrimethylammonium bromide), poly(diaryldimethylammonium chloride/N-isopropylacrylamide), poly(dimethylaminoethyl acrylate/acrylamide), poly(dimethylaminoethyl methacrylate), polydimethylaminoepichlorohydrin, polyethyleneiminoepichlorohydrin, polymethacryloxyethyl-trimethylammonium bromide, hydroxypropylmethacryloyloxyethyl dimethyl ammonium chloride, poly(methyldiethylaminoethylmethacrylate/acrylamide), poly(methyl/guanidine), polymethylvinylpyridinium bromide, poly(vinylpyrrolidone-dimethylaminoethyl methacrylate), or polyvinylmethylpyridinium bromide.

The invention relates to an antithrombin enteric soft capsule preparation which is prepared by using part or all of leech, bloodsucker, whitmania acranulata Whitman, hirudinaria manillensis, dinobdella ferox, Haemadipsa japonica Whitman and Haemadipsa sylvestris as raw materials and other pharmaceutically acceptable auxiliary materials. The preparation method comprises the steps of: 1, preparing powder for preparation; 2, preparing contents in teh soft capsule; and 3, preparing the tenteric soft capsule. The preparation process for the enteric soft capsule preparation has the advantages of improving the stability, improving the transfer rate of effective components, lowering the production stroage requirements, reducing the process difficulty, and has the positive meanings on increasing the stability, quickening the development of the soft capsule preparations, improving the quality, and lowering the production cost.

The purpose of the present invention is to provide an instrument for capturing free thrombi, which can inhibit a blood coagulation reaction at a primary hemostasis stage in which platelet is involved or a coagulated thrombi formation stage in which a blood coagulation factor is involved, whereby it becomes possible to secure the capture of free thrombi and to prolong the usable time of the instrument. The present invention provides: an instrument for capturing free thrombi, in which a compound having an anti-thrombin capability is immobilized on the surface thereof; and a method for capturing free thrombi, which comprises capturing free thrombi in blood in vivo using the instrument for capturing free thrombi.

The invention discloses a preparation method for human antithrombin III (AT-III). The preparation method comprises the following steps: (1) precipitation and dissolution of a blood plasma fraction IV; (2) polyethylene glycol (PEG) precipitation and impure protein removing; (3) DEAE Sephadex A-50 gel adsorption; (4) S/D virus inactivation; (5) heparin affinity column chromatography; (6) ultrafiltration and concentration; (7) addition of a stabilizer and regulation; (8) nanofilm virus-removing filtration; (9) sterilizing filtration; (10) freeze-drying; (11) dry and fever virus inactivation. According to the preparation method, blood coagulation factors, which remain in the raw materials and are depended by vitamin K, are removed, so as to greatly lower the possibility of protein activation in the production process, and improve the product qualification ratio; PEG is adopted for the impure protein removing, so as to reduce the load of a chromatographic column; a liquid obtained from lyophilized powder re-dissolution is clear, transparent, and free of protein precipitation and opalescence; through adoption of a three-step virus inactivation method, the safety of human AT-III for clinical use can be greatly improved.

The invention discloses a protein chip for combined detection of multiple thrombus markers. A preparation method of the protein chip comprises the following steps: (1) black slide pretreatment; (2) antibody solution sample application; (3) a sealing process; and preparation of the protein chip. The protein chip is used for detecting concentrations of various thrombus markers, preventing and reducing thrombus risks and guiding thrombus treatment. The product disclosed by the invention is a protein chip diagnostic kit comprising six indexes of TAT (thrombin-antithrombin complex), PIC (plasmin-alpha2 anti-plasminogen complex), tPAIC (tissue-type plasminogen activator-plasminogen activation inhibition complex), TM (thrombomodulin), FDP (fibrinogen degradation product) and DD (D-dimer). The indexes are detected by using a protein chip technology for the first time, and the method has the advantages of quickness, high efficiency, simplicity, convenience, low cost and the like.

Methods for predicting an individual's genetic risk for developing venous thrombosis in diverse ethnic populations is disclosed, as are arrays and kits which can be used to practice the method. The method includes screening for mutations, polymorphisms, or both, in at least eight venous thrombosis-related molecules, such as antithrombin III, protein C, protein S, fibrinogen, factor V, prothrombin (factor II), methylenetetrahydrofolate reductase (MTHFR), and angiotensin I-converting enzyme (ACE) molecules which are associated with venous thrombosis.

The invention belongs to the field of biotechnology and relates to DTI (Direct thrombin inhibitor) peptides and the application thereof. According to the invention, the molecule of RGD-Hirudin is truncated on the basis of the structure of the RGD-Hirudin, so as to obtain micro-molecule DTI Peptide 1 and micro-molecule DTI Peptide 2. A test and an animal experiment show that the Peptide 1 and the Peptide 2 are DTIs, have antithrombin activity, have definite action target points, have no impact on other blood coagulation factors, can be further used for preparing oral anticoagulant drugs or subcutaneous sustained-release anticoagulant drugs, and particularly suitable for thrombotic disease prevention. The DTI peptides can be taken as candidate drugs for DTIs to be studied intensively, and lay the foundation for developing novel DTIs.

The invention provides the application of heparin sodium to the preparation of an external drug for treating haemorrhoids. The heparin sodium is acid mucopolysaccharide-heparin (The molecular weight is 4000-15000), can interfere with many links in the hemagglutination process and has an anti-coagulation effect both in vivo and in vitro; in combination with antithrombin III (AT-III), the heparin sodium mainly enhances an inhibitory effect of the latter on activated coagulation factors II, IX, X, XI and XII and has the effects of preventing platelet aggregation and damage, hindering the formation of thromboplastin, preventing prothrombin from becoming thrombin and inhibiting thrombin, thereby preventing fibrinogen from becoming fibrinogen and playing an anti-coagulation role. The invention utilizes heparin for dermatology (heparin sodium cream) to treat internal and external hemorrhoids, mixed hemorrhoids and acute thrombotic hemorrhoid and applies the anticoagulation, blood stasis and thrombolysis effects of the heparin sodium to relieve swelling and pain; a blood vessel is dredged, retracted and restored, so that the haemorrhoids is treated. The heparin sodium is applied to an anus(Pay attention to discontinuation when bleeding occurs) and is safe, convenient and effective.

The invention discloses a human anti-thrombin III heparin combination ratio detection method. The detection method comprises the steps of using an efficient size exclusion chromatography column and a sodium salt buffer solution with mobile phases comprising isopropanol and phosphoric acid at pH of 6.0-7.5 to calculate a combination ratio between the human anti-thrombin III and the heparin through a ratio of an area of characteristic peak and a corresponding standard curve; adding inactivated human anti-thrombin III into a standard product of the human anti-thrombin III according to a ratio, and manufacturing a standard curve according to change of the ratio of the area of characteristic peak. According to the method, the human factors are excluded; the accuracy and the precision of results are high, the experiment operation steps are simple, the detection time can be shortened, the experiment cost is reduced and the working efficiency of detectors is greatly improved.